Immunogenicity of SARS-CoV-2 mRNA vaccine in dialysis and kidney transplant patients: A systematic review

Akyol, Merve; Cevik, Enes; Ucku, Duygu; Tanrıöver, Cem; Afsar, Barış; Kanbay, Asiye; Covic, Adrian; Ortíz, Alberto; Basile, Carlo; Kanbay, Mehmet

doi:10.5578/tt.20219612

Cited by 9 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the durability of this immune response and the extent to which it translates to protective immunity remain unclear. A systematic review of 18 studies found that the antibody response to full vaccination with two doses of COVID-19 mRNA vaccines among patients undergoing HD, CAPD and KT was lower than that in the healthy population [27] . In phase 3 trials, BNT162b2, mRNA-1273 and ChAdOx1 nCoV-19 prevented COVID-19 in 95, 94.1 and 70.4% of participants [28] , [29] , [30] , respectively, suggesting that the mRNA vaccines might induce protective immunity more reliably than ChAdOx1 nCoV-19.…”

Section: Discussionmentioning

confidence: 99%

Immune response after COVID-19 vaccination among patients with chronic kidney disease and kidney transplant

Trakarnvanich

Ngamvitchukorn

Phumisantiphong

et al. 2022

Vaccine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Immune response after COVID-19 vaccination among patients with chronic kidney disease and kidney transplant

Trakarnvanich

Ngamvitchukorn

Phumisantiphong

et al. 2022

Vaccine

View full text Add to dashboard Cite

“…The COVID-19 vaccine systematic reviews predominantly used seroconversion as a marker for vaccine efficacy. In general, the studies showed that patients with chronic kidney failure on dialysis (not requiring organ transplantation) [ 10 , 11 , 12 ], immune-mediated inflammatory diseases [ 13 , 14 , 15 , 16 ], and solid tumors [ 17 ] had seroconversion rates that were high and similar to healthy controls (seroconversion rates among patients ranged from about 83% to 97%). In contrast, patients with receipt of anti-CD20 therapy [ 18 ] and solid organ transplants [ 11 , 19 , 20 ] (thus requiring anti-rejection immunosuppression) had markedly low vaccine seroconversion rates (rates ranged from about 26% to 45% after two vaccine doses).…”

Section: Resultsmentioning

confidence: 99%

Vaccination for the Prevention of Infection among Immunocompromised Patients: A Concise Review of Recent Systematic Reviews

See

2022

Vaccines

View full text Add to dashboard Cite

Vaccination is crucial for avoiding infection-associated morbidity and mortality among immunocompromised patients. However, immunocompromised patients respond less well to vaccinations compared to healthy people, and little is known about the relative efficacy of various vaccines among different immunocompromised states. A total of 54 systematic reviews (22 COVID-19; 32 non-COVID-19) published within the last 5 years in Pubmed® were reviewed. They demonstrated similar patterns within three seroconversion response categories: good (about >60% when compared to healthy controls), intermediate (~40–60%), and poor (about <40%). Good vaccine responses would be expected for patients with chronic kidney disease, human immunodeficiency virus infection (normal CD4 counts), immune-mediated inflammatory diseases, post-splenectomy states, and solid tumors. Intermediate vaccine responses would be expected for patients with anti-cytotoxic T-lymphocyte antigen-4 therapy, hematologic cancer, and human immunodeficiency virus infection (low CD4 counts). Poor vaccine responses would be expected for patients with B-cell-depleting agents (e.g., anti-CD20 therapy), hematopoietic stem-cell transplant, solid organ transplant, and liver cirrhosis. For all vaccine response categories, vaccination should be timed when patients are least immunosuppressed. For the intermediate and poor vaccine response categories, high-dose vaccine, revaccination when patients are less immunosuppressed, checking for seroconversion, additional booster doses, and long-acting monoclonal antibodies may be considered, supplemented by shielding measures.

show abstract

“…The detected rise in the seropositivity rates after boosting vaccination can be interpreted in two ways: compensating for the waning immunity after the standard two-dose vaccination, and/or through intensification of the response to the standard protocol. The literature suggests lower seroconversion rates after vaccination against SARS-CoV-2 in both dialysis and KTR patients than that for the healthy controls (27%, 88% and 100%, respectively), with a highly significant difference between the RRT methods [ 64 ]. In the current study, the post-booster seropositivity rates were 41%, 77% and 100% for the KTR, dialysis and healthy controls with patients in both RRT subgroups significantly augmenting seroconversion rates compared to pre-boosting measurements, yet it was only the KTR and not dialysis patients whose seroconversion rates went significantly beyond the levels measured after the standard two doses (Fig.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of booster vaccination against SARS-CoV-2 in dialysis and renal transplant patients: systematic review and meta-analysis

Taheri

2023

Int Urol Nephrol

View full text Add to dashboard Cite

Introduction Patients under renal replacement therapy are at an increased risk of severe infection with SARS-CoV-2, and have been known to have impaired response to standard vaccination. This systematic review and meta-analysis aims at evaluating the efficacy of booster dose vaccination in this population. Methods A systematic review has been conducted to find trials on the booster dose vaccination in kidney transplant recipients (KTRs) or patients under dialysis. Data of seroconversion rates at different timepoints, especially 1 month prior and post-booster dose vaccination have been collected and analyzed. Effects of different factors including type of renal replacement therapy (RRT), vaccine type and brands, magnitude of response to the standard vaccination, and immunosuppression drugs on the response rates have been investigated. Meta-analyses were performed using software Stata v.17. Results Overall 58 studies were included. Both RRT patient subgroups represented significant seroconversion, post- (versus pre-) booster dose vaccination, but only in KTRs the booster dose seroconversion surpassed that of the standard protocol. T-cell response was also significantly augmented after booster vaccination, with no difference between the RRT subgroups. mRNA and vector vaccine types had comparable immunogenicity when employed as boosters, both significantly higher than the inactivated virus vaccine, with no significant disparity regarding the vaccine brands. Patients with poor response to standard vaccination had a significant response to booster dose, with dialysis patients having stronger response. The differential effects of vaccine types and brands in the poor responders was similar to that of the overall RRT population. No rejection episodes or graft failure post-booster vaccination was reported. Conclusion In patients under RRT, booster dose vaccination against SARS-CoV-2 is safe and efficacious determined by significant seroconversion, and therefore, it should be considered to be implemented in all these patients. Since in the KTR patients, the third dose vaccination significantly increased the seroconversion rates even beyond that of the standard protocol, three dose vaccine doses is recommended to be recognized as the standard vaccination protocol in this population. The same recommendation could be considered for dialysis patients, due to their augmented risk of breakthrough infection. Supplementary Information The online version contains supplementary material available at 10.1007/s11255-023-03471-x.

show abstract

Immunogenicity of SARS-CoV-2 mRNA vaccine in dialysis and kidney transplant patients: A systematic review

Cited by 9 publications

References 0 publications

Immune response after COVID-19 vaccination among patients with chronic kidney disease and kidney transplant

Immune response after COVID-19 vaccination among patients with chronic kidney disease and kidney transplant

Vaccination for the Prevention of Infection among Immunocompromised Patients: A Concise Review of Recent Systematic Reviews

Efficacy and safety of booster vaccination against SARS-CoV-2 in dialysis and renal transplant patients: systematic review and meta-analysis

Contact Info

Product

Resources

About